To establish that the therapeutic effects of PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs are not unique to just one target tumor, we used an additional system, OVA-expressing EG7-OVA (EL4 cell line transfected with the gene encoding for OVA) lymphoma cells.22 Seven days after subcutaneous injection of EG7 cells into C57BL/6 mice twice in a week, vaccination with PLGA (OVA+poly I:C)-NPs was performed via the subcutaneous route. Here, CD274 is linked to neoplasm.